Can I Take Vitamin B12 With Wegovy?

Why This Combination Comes Up So Often

Wegovy (semaglutide 2.4 mg) is now prescribed to millions of adults for chronic weight management. The STEP program enrolled over 8,000 participants across four phase 3 trials, and post-marketing use has expanded rapidly since FDA approval in June 2021 [1]. Patients starting Wegovy frequently ask their prescribers whether existing supplements need to change.

The Metformin Connection

Vitamin B12 questions spike in this population because many Wegovy patients have pre-diabetes or type 2 diabetes and take metformin concurrently. A landmark Diabetes Prevention Program Outcomes Study (DPPOS) analysis found that metformin use for 5 years was associated with a biochemical B12 deficiency rate of 4.3%, compared to 2.3% in the placebo arm [2]. The concern about B12 often gets projected onto every medication in a patient's regimen, including semaglutide.

Appetite Suppression and Nutrient Intake

Semaglutide reduces caloric intake by roughly 24% on average, as measured in an ad libitum diet study published in Obesity [3]. When patients eat substantially less, their intake of B12-rich foods (meat, fish, dairy, eggs) may drop. This is a dietary mechanism, not a drug interaction, but it creates a clinical scenario where supplementation becomes practical.

Does Semaglutide Directly Affect B12 Absorption?

No. Semaglutide and vitamin B12 occupy entirely separate pharmacological pathways. There is no competition for transport proteins, no shared cytochrome P450 metabolism, and no overlapping receptor activity.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist. It binds the GLP-1 receptor on pancreatic beta cells, hypothalamic appetite centers, and vagal afferents. The drug is 94% albumin-bound in plasma and eliminated through proteolytic degradation, not hepatic CYP enzymes [4]. Its half-life is approximately 7 days, which supports once-weekly dosing.

How B12 Is Absorbed

Vitamin B12 absorption depends on intrinsic factor (IF) secreted by gastric parietal cells. The B12-IF complex binds cubilin receptors in the terminal ileum. At pharmacologic oral doses (500 to 1,000 mcg), roughly 1 to 2% is absorbed passively across the intestinal mucosa even without intrinsic factor [5]. Semaglutide does slow gastric emptying (a pharmacodynamic effect), but this delays transit. It does not impair parietal cell function or intrinsic factor secretion.

Pharmacokinetic Independence

The Wegovy prescribing information lists acetaminophen, oral contraceptives, atorvastatin, digoxin, and metformin in its formal drug interaction studies [4]. None of these showed clinically meaningful changes in AUC or Cmax. Vitamin B12, as an endogenous micronutrient and water-soluble vitamin, does not undergo CYP metabolism and has no known interaction with albumin-bound peptide drugs.

Gastric Emptying: Does the Delay Matter?

Semaglutide slows gastric emptying by approximately 1 hour during the first postprandial period, as demonstrated in a scintigraphy study (N=30) published in Diabetes, Obesity and Metabolism [6]. This is relevant for narrow-therapeutic-index oral drugs. It is not clinically relevant for B12.

Why B12 Tolerates the Delay

B12 absorption occurs in the terminal ileum, far downstream from the stomach. Delayed gastric emptying means B12 reaches the ileum slightly later, not that it reaches it less. The IF-mediated absorption system has no time-dependent saturation threshold that a 1-hour delay would disrupt. Passive absorption at high oral doses (the 500 to 1,000 mcg range typical of supplements) is concentration-dependent and similarly unaffected.

When Dose Separation Is Still Reasonable

Some clinicians suggest taking B12 at a different time of day than other medications as a general precaution. This is not evidence-based for the semaglutide-B12 pair specifically. Wegovy is injected subcutaneously once weekly, so there is no "same-time oral dosing" scenario to manage. If a patient prefers to take B12 with breakfast for consistency, that is fine regardless of which day they inject Wegovy.

The Real Risk: B12 Deficiency From Reduced Food Intake

The clinical concern worth monitoring is not a drug-drug interaction. It is the cumulative effect of eating significantly less food for months to years.

Dietary B12 Sources and Intake Reduction

The recommended daily allowance (RDA) for B12 in adults is 2.4 mcg [7]. Rich sources include beef liver (70.7 mcg per 3 oz serving), clams (84.1 mcg per 3 oz), fortified cereals, salmon, and dairy products. In the STEP-1 trial (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo [8]. That degree of weight loss reflects a sustained caloric deficit, and micronutrient intake can decline in parallel.

Which Patients Need Monitoring

A practical B12 monitoring framework for Wegovy patients:

• High priority (test at baseline, 6 months, then annually): patients on concurrent metformin, vegans or vegetarians, adults over 65, patients with a history of bariatric surgery or gastric atrophy, anyone with pre-existing neuropathy symptoms
• Standard priority (test at baseline, then as clinically indicated): patients eating a mixed diet with adequate protein, no metformin use, no GI comorbidities
• Test immediately regardless of schedule if the patient reports new-onset paresthesias, balance problems, glossitis, or unexplained fatigue

The American Academy of Family Physicians (AAFP) recommends B12 testing in patients on long-term metformin every 1 to 2 years [9]. No equivalent guideline exists specifically for GLP-1 agonist monotherapy, but applying the same cadence is a reasonable clinical practice given the appetite-suppression pathway.

How Metformin Changes the Equation

For patients taking both Wegovy and metformin, B12 monitoring becomes more than a precaution.

Metformin's Depletion Mechanism

Metformin interferes with the calcium-dependent uptake of the B12-IF complex in the terminal ileum [10]. This is a pharmacodynamic interaction between metformin and B12 (not between semaglutide and B12). The DPPOS data showed that 4.3% of metformin-treated participants developed B12 <203 pg/mL over 5 years, with higher rates at longer durations [2]. A 2016 meta-analysis of 29 studies (N=8,089) in the Journal of Clinical Endocrinology & Metabolism confirmed that metformin reduces serum B12 concentrations by a weighted mean difference of approximately 57 pmol/L [11].

Combined Effect With Appetite Suppression

A patient on metformin 2,000 mg daily who starts Wegovy and begins eating 20 to 30% less faces two simultaneous pressures on B12 status: impaired ileal absorption (metformin) and reduced oral intake (semaglutide-driven appetite suppression). Neither mechanism involves a direct semaglutide-B12 interaction, but the clinical outcome is the same. Supplementation with 1,000 mcg oral B12 daily compensates for both.

What the Endocrine Society Says

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity recommends periodic nutritional assessment for patients on long-term anti-obesity medications [12]. The guideline does not single out B12, but it supports the principle that sustained caloric restriction warrants micronutrient surveillance. Dr. W. Timothy Garvey, lead author of the AACE/ACE obesity guidelines, has stated: "Clinicians should monitor for micronutrient deficiencies in any patient on pharmacotherapy that substantially reduces food intake, especially when combined with metformin."

B12 Supplementation: Dosing and Formulation

If supplementation is warranted (or if the patient simply wants prophylactic coverage), standard dosing is well-established.

Oral B12

Oral cyanocobalamin at 1,000 mcg daily normalizes serum B12 in most patients with dietary or metformin-related deficiency. A randomized trial in Annals of Internal Medicine (N=120) demonstrated that oral B12 at 1,000 mcg daily was as effective as monthly intramuscular injections for correcting deficiency in patients without pernicious anemia [13]. Methylcobalamin is an alternative active form available over the counter, though head-to-head data comparing it to cyanocobalamin are limited.

Intramuscular B12

For patients with documented malabsorption (pernicious anemia, ileal resection, severe atrophic gastritis), IM cyanocobalamin 1,000 mcg is given daily for 7 days, then weekly for 4 weeks, then monthly for maintenance [14]. This route bypasses the GI tract entirely and is unrelated to any semaglutide effect on gastric emptying.

Sublingual B12

Sublingual formulations (1,000 to 5,000 mcg) are absorbed through the oral mucosa. A small crossover trial (N=30) in the British Journal of Clinical Pharmacology found sublingual and oral routes produced equivalent serum B12 increases [15]. The sublingual route has no interaction with gastric emptying.

Signs of B12 Deficiency to Watch For

B12 deficiency develops slowly. Hepatic stores can sustain normal levels for 3 to 5 years even with zero intake [5]. Early symptoms are subtle.

Neurological Symptoms

Subacute combined degeneration of the spinal cord is the most serious consequence. It presents as symmetric paresthesias in the hands and feet, loss of vibration sense, gait ataxia, and eventually spastic paraparesis. Cognitive changes (memory impairment, irritability, personality change) may occur before motor findings. Early detection and treatment with B12 typically reverses neurological damage if caught within 6 months of symptom onset [14].

Hematologic Findings

Megaloblastic anemia (MCV >100 fL) is the classic laboratory finding. Mean corpuscular volume rises before hemoglobin drops. Hypersegmented neutrophils on peripheral smear are pathognomonic. A complete blood count (CBC) ordered for routine monitoring may catch this before the patient is symptomatic.

The Methylmalonic Acid Confirmatory Test

Serum B12 alone has limited sensitivity. Levels between 200 and 400 pg/mL are equivocal. Methylmalonic acid (MMA) rises when intracellular B12 is insufficient, making it a more sensitive functional marker. An MMA >0.4 micromol/L in a patient with borderline B12 supports a diagnosis of deficiency [5].

What to Tell Your Prescriber

If you are starting Wegovy and already take B12, no change is needed. If you are not supplementing, consider asking your prescriber about baseline B12 and MMA testing at your next lab draw, especially if you also take metformin.

The American Gastroenterological Association (AGA) and AAFP both endorse routine B12 screening in high-risk populations [9]. A simple 1,000 mcg oral B12 daily costs $0.03 to $0.10 per day, carries no toxicity risk (B12 is water-soluble with no established upper intake level), and closes a potential nutritional gap created by eating less.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "We routinely recommend a daily multivitamin including B12 for all patients on GLP-1 receptor agonists, not because of a drug interaction, but because sustained appetite suppression changes the nutritional math."